Sign in

tanyabondar.bsky.social

@tanyabondar.bsky.social
41 followers 86 following 12 posts
PostsRepliesMedia
Reposted by @tanyabondar.bsky.social
Mark Hartmann @mphartmann.bsky.social · 06/12/2025
ONLINE FIRST ALERT! Molecular #Plasticity Results in #Oncofetal #Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia aacrjournals.org/bloodcancerd... @aacrjournals.bsky.social #childhoodcancer #epigenetics #precisiononcology
3216
Reposted by @tanyabondar.bsky.social
AACR Journals @aacrjournals.bsky.social · 07/12/2025
Read this recently published In Focus article— The Global State of Blood Cancers: An Ongoing Challenge, adapted from the 15th edition of the annual AACR Cancer Progress Report. buff.ly/ttfKgFy #ASH25
002
Reposted by @tanyabondar.bsky.social
Daniel Lipka @dblipka.bsky.social · 06/12/2025
Very happy and proud to see this story finally published! 🎉🥳 #epigenetics #hematology #jmml #leukemia
0101
Reposted by @tanyabondar.bsky.social
AACR Journals @aacrjournals.bsky.social · 19/09/2025
Attending the #IMS25 Regulatory Session? Check out this review article on how MRD received FDA approval as an early endpoint for myeloma and what this means for accelerated drug approval: buff.ly/jCeKyZp
011
Reposted by @tanyabondar.bsky.social
AACR Journals @aacrjournals.bsky.social · 21/09/2025
Paola Neri presents data from her recent Blood Cancer Discovery paper, "Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapies" at #IMS25. Read the article: buff.ly/vlQra5A
042
Reposted by @tanyabondar.bsky.social
Anand Patel @anand-88-patel.bsky.social · 04/06/2025
another illustrative study of "one-size-fits all" prognostic stratification in acute leukemia doesn't always work! The prognostic value of gene mutations commonly thought to impact risk in African-ancestry patients with T-ALL was limited! aacrjournals.org/bloodcancerd...
001
tanyabondar.bsky.social @tanyabondar.bsky.social · 16/09/2025
000
Reposted by @tanyabondar.bsky.social
AACR Journals @aacrjournals.bsky.social · 01/07/2025
Louis M. Staudt, M.D., Ph.D., has pioneered molecular classification of cancers, specifically lymphomas. Speaking with Blood Cancer Discovery’s Abigail Cleveland, Dr. Staudt shares his career experience on the path to scientific discovery. Read the Q&A:
buff.ly
011
Reposted by @tanyabondar.bsky.social
AACR Journals @aacrjournals.bsky.social · 09/07/2025
In this recent Blood Cancer Discovery article by @morinryan.bsky.social, DNA methylation profiling reveals two BL epitypes with distinct molecular and clinical features, offering a new framework for understanding BL pathogenesis. Read the study: buff.ly/PGqUMvz
112
Reposted by @tanyabondar.bsky.social
AACR Journals @aacrjournals.bsky.social · 12/07/2025
AACR Journals in the news: buff.ly/1p578T3 In this Blood Cancer Discovery study, Teclistamab-cqyv led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. Check it out: buff.ly/wMmq7EK
012
Reposted by @tanyabondar.bsky.social
AACR Journals @aacrjournals.bsky.social · 26/08/2025
Read this collection of impactful Blood Cancer Discovery articles that highlight advanced lymphoma research by leveraging novel tools and techniques, uncovering molecular networks that drive oncogenesis and progression, and bringing innovative therapies to patients. buff.ly/q3NmZc2
032
Reposted by @tanyabondar.bsky.social
AACR Journals @aacrjournals.bsky.social · 27/08/2025
Congratulations to Courtney D. DiNardo, MD, MSCE, and colleagues, recipients of the 2025 Blood Cancer Discovery Award for Outstanding Journal Article. Learn more and read the article: buff.ly/43MI9n0
001
tanyabondar.bsky.social @tanyabondar.bsky.social · 18/08/2025
001
tanyabondar.bsky.social @tanyabondar.bsky.social · 18/08/2025
000
tanyabondar.bsky.social @tanyabondar.bsky.social · 18/08/2025
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study doi.org/10.1158/2643...
000
tanyabondar.bsky.social @tanyabondar.bsky.social · 18/08/2025
1,157 people with TP53-CHIP from BioBankJapan followed over a decade (vs 140,000 controls), TP53-CHIP associated with myeloid, lymphoid neoplasms, respiratory disease mortality. The impact is modulated by lifestyle (smoking and drinking). Stay healthy! #clonalhematopoiesis doi.org/10.1158/2643...
000
tanyabondar.bsky.social @tanyabondar.bsky.social · 18/08/2025
Now online @BCD_AACR: Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma #MMsm #CARTcell #microbiome #immunotherapy aacrjournals.org/bloodcancerd...
010
Reposted by @tanyabondar.bsky.social
elvinwag.bsky.social @elvinwag.bsky.social · 28/04/2025
Check out our new 'In Focus' article on overcoming B-cell acute lymphoblastic leukemia resistance by combining targeted and immune therapies in Blood Cancer Discovery! Big shoutout to Miguel and Grace for their fantastic work. t.co/bBuHxhKgCf
001
Reposted by @tanyabondar.bsky.social
Amy Pomeroy @amypomeroy.bsky.social · 10/04/2025
I am so excited to share that our new paper is out! A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma Out in Blood Cancer Discovery doi.org/10.1158/2643-3230.BCD-24-0230 #mathonc #lymsm #BloodCancer 1/n
doi.org
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Abstract. Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patien...
174
tanyabondar.bsky.social @tanyabondar.bsky.social · 01/04/2025
docs.google.com/document/d/1...
docs.google.com
Public Statement on Supporting Science for the Benefit of All Citizens
TO THE AMERICAN PEOPLE We all rely on science. Science gave us the smartphones in our pockets, the navigation systems in our cars, and life-saving medical care. We count on engineers when we drive acr...
000
Reposted by @tanyabondar.bsky.social
American Association for Cancer Research (AACR) @theaacr.bsky.social · 26/03/2025
Cures in Crisis: Senators Baldwin and Welch hosted a forum featuring researchers, patients, and former NIH Director Monica Bertagnolli, MD, discussing the impact of recent NIH disruptions on scientific progress and patient care. Watch the recap: www.youtube.com/live/JofqSdW... @baldwin.senate.gov
1164
Reposted by @tanyabondar.bsky.social
Herranz Lab @herranzlab.bsky.social · 21/03/2025
Happy to share our In Focus comment on targeting metabolism in T-ALL in #BloodCancerDiscovery, single-handedly written by @dasilva-diz.bsky.social! Thanks for the invitation to write on such an exciting topic @tanyabondar.bsky.social! @rutgerscancer.bsky.social aacrjournals.org/bloodcancerd...
054
tanyabondar.bsky.social @tanyabondar.bsky.social · 20/03/2025
Trees don't have p53, yet are cancer-free. No malignancies, despite huge exposures to sunlight. Can we learn from a tree how to stay cancer-free?
000
tanyabondar.bsky.social @tanyabondar.bsky.social · 12/03/2025
And as this is a relapse, it is spreading and damaging vital organs at a much faster pace that the first occurrence. It also appears resistant to conventional treatments.
010
Reposted by @tanyabondar.bsky.social
Eric Topol @erictopol.bsky.social · 06/03/2025
GLP-1 drugs association with reduced risk of blood cancers (leukemias and lymphomas) jamanetwork.com/journals/jam...
415727
Reposted by @tanyabondar.bsky.social
Eric Topol @erictopol.bsky.social · 10/03/2025
Not enough to cut funding. Now a list of over 20 health and life science topics that cannot be published by National Cancer Institute scientists without "oversight" (i.e. censorship).
12317197
Reposted by @tanyabondar.bsky.social
Jonathan Kagan @jkagan1.bsky.social · 15/02/2025
If our "academic leaders" are wondering what a real leader looks like, look no further. Who will follow Dr. Varmus? www.nytimes.com/2025/02/14/o...
nytimes.com
Opinion | American Science is Under Attack (Gift Article)
The Trump administration hobbles research and endangers the public health.
0126
Reposted by @tanyabondar.bsky.social
David Steensma, MD @davidsteensma.bsky.social · 22/11/2024
Hematologists & pathologists find these cells fascinating: ring sideroblasts. While most commonly associated with #MDS or inherited genetic disorders like #XLSA or #MLASA, these cells can also result from ethanol or tuberculosis drugs - even hypothermia. They have such an interesting history!/1
Ring sideroblasts (Prussian blue reaction) in a bone marrow aspirate.  Image source: @ash-hematology.bsky.social Image Bank
2135
Reposted by @tanyabondar.bsky.social
danapeer.bsky.social @danapeer.bsky.social · 11/03/2025
Congratulations to the new fellows.
033
tanyabondar.bsky.social @tanyabondar.bsky.social · 12/03/2025
It is an honor to be a part of the excellent #MyeloidMalignancies25 conference organized by @rosslevinemd.bsky.social and Iannis Aifantis. Stellar scientific program, stunning venue. Check it out! There is still time to register until Thursday at bit.ly/3ZpUESA @fusionconf.bsky.social
010
Reposted by @tanyabondar.bsky.social
djmurphylab2.bsky.social @djmurphylab2.bsky.social · 02/12/2024
A little MYC goes a long way! Check out our collaborator's paper in Blood Cancer Discovery: doi.org/10.1158/2643...
doi.org
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis
c-MYC copy number gain due to trisomy 8 drives S100A9-mediated inflammation and expansion of hematopoietic stem cells and progenitors in the bone marrow, thus trisomy 8 defines a new subset of myelopr...
062